S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

BioMarin Pharmaceutical (BMRN) Competitors

$91.51
-0.71 (-0.77%)
(As of 04/15/2024 ET)

BMRN vs. ALNY, IONS, MDGL, ALKS, TEVA, BGNE, VTRS, GMAB, KRTX, and RDY

Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Genmab A/S (GMAB), Karuna Therapeutics (KRTX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.

BioMarin Pharmaceutical vs.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.8% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 1.4% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 6.93% compared to Alnylam Pharmaceuticals' net margin of -24.08%. BioMarin Pharmaceutical's return on equity of 5.01% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical6.93% 5.01% 3.64%
Alnylam Pharmaceuticals -24.08%N/A -12.18%

BioMarin Pharmaceutical received 445 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.16% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.83% of users gave BioMarin Pharmaceutical an outperform vote.

CompanyUnderperformOutperform
BioMarin PharmaceuticalOutperform Votes
1531
74.83%
Underperform Votes
515
25.17%
Alnylam PharmaceuticalsOutperform Votes
1086
76.16%
Underperform Votes
340
23.84%

BioMarin Pharmaceutical has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.

BioMarin Pharmaceutical presently has a consensus price target of $107.61, indicating a potential upside of 15.45%. Alnylam Pharmaceuticals has a consensus price target of $216.12, indicating a potential upside of 45.97%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical
0 Sell rating(s)
7 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.63
Alnylam Pharmaceuticals
0 Sell rating(s)
8 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.56

BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$2.42B7.22$167.65M$0.88105.11
Alnylam Pharmaceuticals$1.83B10.25-$440.24M-$3.56-41.81

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 9 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 0.58 beat BioMarin Pharmaceutical's score of 0.53 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioMarin Pharmaceutical
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRN vs. The Competition

MetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17.46B$6.33B$4.65B$7.48B
Dividend YieldN/A3.10%5.44%3.95%
P/E Ratio105.119.05194.9815.64
Price / Sales7.22315.972,398.3089.16
Price / Cash51.5520.2532.7728.16
Price / Book3.525.584.684.48
Net Income$167.65M$136.09M$98.55M$209.88M
7 Day Performance5.98%-4.80%-4.00%-3.47%
1 Month Performance10.29%-4.05%-2.43%0.89%
1 Year Performance-6.58%2.71%13.10%7.58%

BioMarin Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALNY
Alnylam Pharmaceuticals
4.471 of 5 stars
$155.90
-0.1%
$216.12
+38.6%
-27.6%$19.64B$1.83B-43.792,100Analyst Upgrade
Analyst Revision
IONS
Ionis Pharmaceuticals
4.1384 of 5 stars
$42.83
+1.4%
$55.92
+30.6%
+12.3%$6.16B$787.65M-16.73927
MDGL
Madrigal Pharmaceuticals
4.6349 of 5 stars
$249.34
+0.3%
$377.40
+51.4%
-3.5%$4.96BN/A-12.50376Analyst Upgrade
ALKS
Alkermes
3.8021 of 5 stars
$26.73
+3.1%
$33.14
+24.0%
-18.2%$4.47B$1.66B12.912,100Analyst Revision
High Trading Volume
TEVA
Teva Pharmaceutical Industries
1.356 of 5 stars
$13.98
-1.5%
$13.78
-1.4%
+59.6%$15.67B$15.85B-29.7337,851
BGNE
BeiGene
1.6409 of 5 stars
$154.02
+2.9%
$251.70
+63.4%
-47.6%$14.72B$2.46B-18.1210,600Gap Up
VTRS
Viatris
1.1024 of 5 stars
$11.82
+0.6%
$11.00
-6.9%
+14.7%$14.18B$15.43B295.5038,000
GMAB
Genmab A/S
3.6443 of 5 stars
$29.97
+0.4%
$48.50
+61.8%
-29.0%$19.80B$2.39B31.222,204Short Interest ↑
KRTX
Karuna Therapeutics
0.1424 of 5 stars
$329.83
flat
$293.92
-10.9%
+80.6%$12.58B$654,000.00-28.14339
RDY
Dr. Reddy's Laboratories
2.1502 of 5 stars
$73.85
+0.2%
$80.00
+8.3%
+18.4%$12.32B$2.99B19.4925,863

Related Companies and Tools

This page (NASDAQ:BMRN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners